UTHR (United Therapeutics) Tax Provision: $-321 Mil (TTM As of Mar. 2026)


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $547.06
GF Value $387.00
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Tax Provision?

United Therapeutics UTHR -0.98% 88 Tax Provision is $-321 Mil as of Mar. 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $387.00 (Significantly Overvalued). The stock has 7 warning signs investors should review.

United Therapeutics's tax provision for the three months ended in Mar. 2026 was $-43 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $-321 Mil.

United Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Tax Provision Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -118.10 -223.30 -289.50 -343.90 -379.20

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.30 -98.90 -99.30 -79.70 -43.40
UTHR
88GF Score
United Therapeutics Corp UTHR
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-321 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-321 Mil mean?
United Therapeutics (UTHR) has a Tax Provision of $-321 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Tax Provision too high?
United Therapeutics' current Tax Provision is $-321 Mil. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Tax Provision compare to VTRS and NBIX?
United Therapeutics' Tax Provision of $-321 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on United Therapeutics and its competitors. United Therapeutics's current Tax Provision is $-321 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.00, compared to a current price of $547.06 — trading 41.4% above its estimated fair value. The current Tax Provision is $-321 Mil. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Tax Provision is $-321 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $547.06 is trading 41.4% above its estimated GF Value™ of $387.00. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Tax Provision: $-321 Mil
  • GF Value™: $387.00 vs. price of $547.06 (41.4% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$547.06
Price
$387.00
GF Value